Risperidone in schizophrenia

Abuzzahab FS, Gillund JM. Clozapine and risperidone in schizophrenia. Poster presentation at the 33rd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1994. 

Woodward ND et al A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005 8 457. [PMID 15784157]... 

Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharma-col. 2004 14 87-92. 

Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, Le Jeunne C, Naber D, Priori S, Sturkenboom M, Thibaut F, Peuskens J, Mittoux A, Tanghpj P, Toumi M, Moore ND, Mann RD. Safety of sertin-dole versus risperidone in schizophrenia principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010 122 345-55. 

Almond S, O Donnell O, McKendrick J (1999). A cost analysis of olanzapine compared with haloperidol and risperidone in the treatment of schizophrenia in the UK. Poster presented at the 12th Congress of the European College of Neuropsychopharmacology, London, 21-25 September 1999. 

Gregor K, Gureje O, Lambert T, et al (1999). Olanzapine versus risperidone in the management of schizophrenia a randomized double-blind study in Australia and New Zealand. Abstract presented at the Xlth World Congress of Psychiatry, Hamburg,... 

Tran PV, Hamilton SH, KuntzAJ, et al (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. 

Jeste DV, Klausner M, Brecher M, et al (1996). A clinical evaluation of risperidone in the treatment of schizophrenia a ten week open label multicentre trial. Psychopharmacology... 

Lane, H. Y. et al. (2001). A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia. /. Clin. Psychiatry, 62, 994-5. 

Xing, Q. et al. (2006b). Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics, 7, 987-93. 

Huang, Y., Liu, X. H., Xu, K. et al. (2002b). Association study of cytochrome P450 2D6 gene polymorphism and therapeutic response to risperidone in Chinese subjects with schizophrenia. Journal of Chinese Psychiatry, 35(2), 103-6. 

Patel, N. C., Crismon, M. L., Shafer, A., De Leon, A., Lopez, M. et al. (2006). Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders. Soc. Psychiatry. Psychiatr. Epidemiol., 41, 341-6. 

Figure 12.1 Cost of atypical antipsychotic drugs (clozapine and risperidone) in each country/territory for patients with schizophrenia...

The preliminary findings of a relationship between serotonin S-HTja receptor genotype and atypical antipsychotic responsiveness in schizophrenia warrant replication and could be extended to children and adolescents with autism. Investigation along these lines has been included in the (National Institute of Mental Health (NIMH)-sponsored multicenter study of risperidone in autism (Arnold et ah, 2000). 

Armenteros, J.L., Whitaker, A.H., Welikson, M., Stedge, D.J., and Gorman,/. (1997) Risperidone in adolescents with schizophrenia an open pilot study. / Am Acad Child Adolesc Psychiatry 36 694— 700. 

Several case reports suggest good efficacy of risperidone in child and adolescent schizophrenia (for review see Toren et al., 1998). 

Quintana H. and Keshavan, M. (1995) Case study risperidone in children and adolescents with schizophrenia. / Am Acad Child Adolesc Psychiatry. 34 1292-1296. 

Atypical neuroleptics. Because of the limited effectiveness and safety of conventional neuroleptics in TS, clinicians have turned to a new generation of neuroleptics that have been introduced for the treatment of schizophrenia. Risperidone, a member of a class of antipsychotics that blocks both DA and serotonin receptors, has been established as superior to placebo and equal, or superior, to haloperidol in the treatment of schizophrenia (Chouinard et al. 1993 Marder and Meibach 1994]. Risperidone has a more favorable side-effect profile than that of conventional neuroleptics and may have less potential for producing tardive dyskinesia. Compared with haloperidol, fewer extrapyramidal side effects are observed with risperidone in doses of 6 mg/ day or less. As encouraging reports appear in the literature (Lombroso et al. 1995 Stamenkovic et al. 1994 van der Linden et al. 1994], risperidone is currently being widely used by clinicians to treat tic disorders. 

Kopala L, Honer WG Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia (letter). Am J Psychiatry 151 1714-1715, 1994... 

Marder SR, Meibach RC Risperidone in the treatment of schizophrenia. Am J Psychiatry 151 825-835, 1994... 

Some published examples illustrating the use of (biasing) high doses of standard drug are trials with risperidone in the treatment of schizophrenia, with haloperidol used as a comparator (Chouinard et al, 1993 Marder and... 

Therapeutic Efficacy. The therapeutic efficacy of risperidone for schizophrenia has been well established in several controlled trials conducted worldwide ( 74, 75). The clinical efficacy trials performed to support approval of risperidone by regulatory agencies have all been published. Therefore, it is appropriate to combine these data using meta-analytic techniques to explore the efficacy of risperidone compared with neuroleptics. For most drugs, the relationship of dose and response is defined by the classic sigmoidal curve. Thus, as the dose (or plasma level) increases beyond a threshold and reaches the linear portion of the curve, response increases. Once the dose is high enough to produce maximal clinical response, the dose-response curve then levels off. 

Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT 2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999 156 286-293. 

Csernansky J, Okamoto A. Risperidone vs haloperidol for prevention of relapse in schizophrenia and schizoaffective disorder. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, Acapulco, December 12-16,1999. 

Lane HY, Chiu WC, Chou JC, et al. Risperidone in acutely exacerbated schizophrenia dosing strategies and plasma levels. J Clin Psychiatry 2000 61 209-214. 

---